# Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

> **NCT00002032** · NA · COMPLETED · sponsor: **Pharmacia** · enrollment: 750 (—)

## Conditions studied

- Mycobacterium Avium-intracellulare Infection
- HIV Infections

## Interventions

- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT00002032
- **Lead sponsor:** Pharmacia
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 750 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002032, "Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00002032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*